Produce a Stakeholder Summary

Lead with the decision and its conditions. A compact summary should include:

• treated geography, outcome, launch, cooldown, and measurement dates;
• eligible donor universe and material exclusions;
• design-stage MDE at the stated target power and plausible lift range;
• inference status, ATT in outcome units, interval, p-value, and placebo count;
• pre-period fit and donor concentration;
• concurrent media, spillover, data, and sensitivity caveats;
• a clear recommendation: proceed, interpret cautiously, redesign, or reject.

Example:

GeoSC estimated average incremental revenue of £X per week against the pre-specified SparseSC counterfactual over dates A–B. The two-sided in-space placebo p-value was P using N placebo assignments; the interval was [L, U]. Interpretation is conditional on the recorded donor-eligibility and treatment- isolation assumptions. The design-stage grid-based MDE was M% at T% target power, with smaller tested effects below the target in that run. This does not assess untested effects or validate the DGP.

Do not translate statistical significance into ROI without campaign cost and a commercial value definition. Do not describe status: ok as proof of causal validity.